Innovent Biologics

Innovent Biologics

Innovent Biologics was founded in 2011 by 俞德超, a scientist and entrepreneur who previously held roles at major pharma and biotech firms. The company was established in Suzhou, China, and its mission is to develop high-quality, affordable biologics for patients with limited treatment options. The firm's lead product is mazdutide, a GCG/GLP-1 dual receptor agonist for weight loss and diabetes — approved in June 2025 by China's NMPA for weight management, with a diabetes indication following in September 2025. Innovent deploys capital across biotech R&D, clinical-stage assets, and manufacturing capabilities. Its pipeline spans 37 drug candidates across oncology, metabolic disease, and other areas. Confirmed asset classes include biologic drugs, small molecules, and next-generation peptide therapeutics. The firm has 18 approved drugs and 8 that received China's 'Major New Drug Creation' national priority programs. Geographically, Innovent focuses on China — with R&D and commercial operations in Suzhou, Shanghai, and Beijing, plus smaller offices in London and New York. As of March 2026, the company reported a 2,000-plus-person R&D team and 18 approved medicines. The firm has been recognized repeatedly: it received MSCI's top ESG rating (AAA) in both 2024 and 2025. In 2022, it was named to Forbes China's top 50 innovative companies. A landmark event was winning China's Patent Gold Award in 2021 for its PD-1 antibody patent. Innovent's structural differentiator is its vertically integrated R&D and manufacturing platform — controlling the full chain from target discovery to late-stage clinical development and commercial manufacturing. This is unusual among Chinese biotechs, which typically license or outsource manufacturing. The company also leverages partnerships with international pharma firms and academic institutions to access novel targets and technology platforms.